CU24410B1 - Benzimidazol-2-aminas como inhibidores de midh1 - Google Patents
Benzimidazol-2-aminas como inhibidores de midh1Info
- Publication number
- CU24410B1 CU24410B1 CU2016000120A CU20160120A CU24410B1 CU 24410 B1 CU24410 B1 CU 24410B1 CU 2016000120 A CU2016000120 A CU 2016000120A CU 20160120 A CU20160120 A CU 20160120A CU 24410 B1 CU24410 B1 CU 24410B1
- Authority
- CU
- Cuba
- Prior art keywords
- sup
- benzimidazol
- aminas
- midh1
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 abstract 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 abstract 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14154680 | 2014-02-11 | ||
| EP14182002 | 2014-08-22 | ||
| PCT/EP2015/052676 WO2015121210A1 (en) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines as midh1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160120A7 CU20160120A7 (es) | 2016-12-23 |
| CU24410B1 true CU24410B1 (es) | 2019-05-03 |
Family
ID=52462928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000120A CU24410B1 (es) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-aminas como inhibidores de midh1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9957235B2 (enExample) |
| EP (1) | EP3105209B1 (enExample) |
| JP (1) | JP6534675B2 (enExample) |
| KR (1) | KR20160115991A (enExample) |
| CN (1) | CN106573897B (enExample) |
| AP (1) | AP2016009371A0 (enExample) |
| AU (1) | AU2015217788B2 (enExample) |
| BR (1) | BR112016018604A2 (enExample) |
| CA (1) | CA2939026A1 (enExample) |
| CL (1) | CL2016002033A1 (enExample) |
| CR (1) | CR20160361A (enExample) |
| CU (1) | CU24410B1 (enExample) |
| DO (1) | DOP2016000208A (enExample) |
| EA (1) | EA031655B1 (enExample) |
| IL (1) | IL246785A0 (enExample) |
| MX (1) | MX2016010474A (enExample) |
| PE (1) | PE20170143A1 (enExample) |
| PH (1) | PH12016501581A1 (enExample) |
| SG (1) | SG11201605810WA (enExample) |
| SV (1) | SV2016005257A (enExample) |
| TW (1) | TWI666202B (enExample) |
| UY (1) | UY35991A (enExample) |
| WO (1) | WO2015121210A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| WO2015121210A1 (en) | 2014-02-11 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| EP3194383B1 (en) | 2014-09-19 | 2019-11-06 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| CN107108554B (zh) * | 2014-10-23 | 2020-11-06 | 德国癌症研究中心 | 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑 |
| US10138226B2 (en) * | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CA2988356A1 (en) * | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| CA2991360A1 (en) * | 2015-07-07 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
| CA2992364A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201718513A (zh) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
| TW201708193A (zh) * | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑 |
| EP3414224B1 (en) * | 2016-02-09 | 2022-03-23 | InventisBio LLC | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
| WO2019015672A1 (zh) * | 2017-07-21 | 2019-01-24 | 南京明德新药研发股份有限公司 | 吡啶并咪唑类化合物及其应用 |
| CA3070878A1 (en) | 2017-08-01 | 2019-02-07 | Deutsches Krebsforschungszentrum | Combination of midh1 inhibitors and dna hypomethylating agents (hma) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| EA202190009A1 (ru) * | 2018-06-26 | 2021-03-25 | Кпс Фармасьютикалз, Инк. | Производные бензимидазола и их применение в качестве ингибиторов idh1 |
| TWI760017B (zh) * | 2019-12-23 | 2022-04-01 | 大陸商昆藥集團股份有限公司 | 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| TW202216139A (zh) | 2020-07-21 | 2022-05-01 | 日商第一三共股份有限公司 | 帝盟多與變異型ｉｄｈ１酵素阻礙劑之組合藥 |
| CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| CN1161340C (zh) | 1998-11-30 | 2004-08-11 | 先灵公司 | 为玻连蛋白受体拮抗剂的苯并咪唑化合物 |
| US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム （カナダ） リミテッド | ウイルスポリメラーゼインヒビター |
| AU2003220970A1 (en) | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| WO2005044793A2 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| WO2006038738A1 (ja) | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| US7893267B2 (en) | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
| WO2009116074A2 (en) | 2008-02-13 | 2009-09-24 | Cadila Healthcare Limited | Substituted benzimidazoles as cannabinoid modulator |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2010151441A1 (en) * | 2009-06-23 | 2010-12-29 | Translational Genomics Research Institute | Benzamide derivatives |
| JP5967827B2 (ja) | 2009-12-09 | 2016-08-10 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物 |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103435554A (zh) * | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-苯氨基苯并咪唑类化合物及其用途 |
| WO2015121210A1 (en) | 2014-02-11 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CN107108554B (zh) | 2014-10-23 | 2020-11-06 | 德国癌症研究中心 | 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑 |
| US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| HK1248070A1 (zh) | 2015-05-18 | 2018-10-12 | 转化药物开发有限责任公司 | 作为激酶抑制剂的杂环化合物 |
| JP7028765B2 (ja) | 2015-05-22 | 2022-03-02 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | ベンズアミドおよび活性化合物組成物および使用方法 |
| CA2988356A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| CA2991360A1 (en) | 2015-07-07 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
| CA2992364A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑 |
| TW201718513A (zh) | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
| CA3053238A1 (en) | 2016-03-02 | 2017-09-08 | Translational Drug Development Llc | Aminobenzimidazole derivatives |
-
2015
- 2015-02-10 WO PCT/EP2015/052676 patent/WO2015121210A1/en not_active Ceased
- 2015-02-10 SG SG11201605810WA patent/SG11201605810WA/en unknown
- 2015-02-10 US US15/118,154 patent/US9957235B2/en active Active
- 2015-02-10 CA CA2939026A patent/CA2939026A1/en not_active Abandoned
- 2015-02-10 JP JP2016551221A patent/JP6534675B2/ja not_active Expired - Fee Related
- 2015-02-10 AP AP2016009371A patent/AP2016009371A0/en unknown
- 2015-02-10 CN CN201580019265.9A patent/CN106573897B/zh not_active Expired - Fee Related
- 2015-02-10 MX MX2016010474A patent/MX2016010474A/es unknown
- 2015-02-10 AU AU2015217788A patent/AU2015217788B2/en not_active Ceased
- 2015-02-10 PE PE2016001465A patent/PE20170143A1/es unknown
- 2015-02-10 BR BR112016018604A patent/BR112016018604A2/pt not_active Application Discontinuation
- 2015-02-10 EA EA201691590A patent/EA031655B1/ru not_active IP Right Cessation
- 2015-02-10 CU CU2016000120A patent/CU24410B1/es unknown
- 2015-02-10 CR CR20160361A patent/CR20160361A/es unknown
- 2015-02-10 EP EP15703288.9A patent/EP3105209B1/en active Active
- 2015-02-10 KR KR1020167024825A patent/KR20160115991A/ko not_active Withdrawn
- 2015-02-11 UY UY0001035991A patent/UY35991A/es not_active Application Discontinuation
- 2015-02-11 TW TW104104623A patent/TWI666202B/zh not_active IP Right Cessation
-
2016
- 2016-07-14 IL IL246785A patent/IL246785A0/en unknown
- 2016-08-10 PH PH12016501581A patent/PH12016501581A1/en unknown
- 2016-08-11 SV SV2016005257A patent/SV2016005257A/es unknown
- 2016-08-11 CL CL2016002033A patent/CL2016002033A1/es unknown
- 2016-08-11 DO DO2016000208A patent/DOP2016000208A/es unknown
-
2018
- 2018-03-16 US US15/923,895 patent/US10442772B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20190062285A1 (en) | 2019-02-28 |
| JP6534675B2 (ja) | 2019-06-26 |
| JP2017505790A (ja) | 2017-02-23 |
| PH12016501581A1 (en) | 2017-02-06 |
| DOP2016000208A (es) | 2016-09-15 |
| KR20160115991A (ko) | 2016-10-06 |
| IL246785A0 (en) | 2016-08-31 |
| UY35991A (es) | 2015-09-30 |
| EP3105209B1 (en) | 2019-08-21 |
| SG11201605810WA (en) | 2016-08-30 |
| AP2016009371A0 (en) | 2016-08-31 |
| TWI666202B (zh) | 2019-07-21 |
| TW201613874A (en) | 2016-04-16 |
| CA2939026A1 (en) | 2015-08-20 |
| CR20160361A (es) | 2016-10-03 |
| EA031655B1 (ru) | 2019-02-28 |
| EA201691590A1 (ru) | 2017-02-28 |
| AU2015217788B2 (en) | 2019-06-27 |
| WO2015121210A1 (en) | 2015-08-20 |
| CU20160120A7 (es) | 2016-12-23 |
| BR112016018604A2 (pt) | 2017-08-08 |
| PE20170143A1 (es) | 2017-03-19 |
| US9957235B2 (en) | 2018-05-01 |
| US10442772B2 (en) | 2019-10-15 |
| CN106573897A (zh) | 2017-04-19 |
| CN106573897B (zh) | 2019-09-24 |
| US20170197921A1 (en) | 2017-07-13 |
| MX2016010474A (es) | 2016-10-31 |
| CL2016002033A1 (es) | 2017-03-31 |
| SV2016005257A (es) | 2018-10-02 |
| EP3105209A1 (en) | 2016-12-21 |
| AU2015217788A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| PH12018500177A1 (en) | Compositions useful for treating disorders related to kit and pdfgr | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| MX2017008442A (es) | Uso de picolinamidas como fungicidas. | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| ECSP15045801A (es) | Inhibidores de la phd de 6(5hidroxi1hpirazol1il)nicotinamida | |
| MA40076A (fr) | Inhibiteurs de syk | |
| DOP2017000278A (es) | Piridinas sustituidas y método de uso | |
| GT201800020A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| CL2017001650A1 (es) | Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis. | |
| EA201690844A1 (ru) | Ингибиторы gsk-3 | |
| DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
| UY36070A (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| CU20160003A7 (es) | Pirazololpiridinaminas sustituidas | |
| CL2017000312A1 (es) | Elección de microarn como diana para trastornos metabólicos | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa |